Dyne Therapeutics
Tracked across 1 events · 6 articles · First seen Jun 03, 2026 · Last active Jun 03, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Dyne Therapeutics announced the completion of enrollment in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial for zeleciment basivarsen (DYNE-101), an investigational therapeutic for Myotonic dystrophy type 1 (DM1). The cohort enrolled 71…
Impact: Dyne Therapeutics announced the completion of enrollment in the registrational expansion cohort of its ACHIEVE trial for zeleciment basivarsen, a significant step towards potential market approval and commercialization of a treatment for Myotonic Dystrophy Type 1 (DM1). This milestone could positively impact the company's stock price and future revenue streams.
Jun 03, 2026 · 6 articles
100
Dyne Therapeutics completed enrollmentDyne Therapeutics...
80
Dyne Therapeutics planned data releaseDyne Therapeutics...
70
United States — Food and Drug Administration granted designations Dyne TherapeuticsDyne Therapeutics...
60
Dyne Therapeutics pursues approval pathwaysDyne Therapeutics...
40
European Union — European Medicines Agency granted designation Dyne TherapeuticsDyne Therapeutics...
40
Bangladesh — Ministry of Health and Family Welfare granted designation Dyne TherapeuticsDyne Therapeutics...
NEWSDESK
Track Dyne Therapeutics live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard